Literature DB >> 7270780

Temporal artery biopsy in giant-cell arteritis. A reappraisal.

C J Allsop, P J Gallagher.   

Abstract

We have reviewed the clinical records and histology of 135 patients who underwent temporal artery biopsy between 1973 and 1978. Biopsies were classified histologically as giant-cell arteritis (17%), atypical arteritis (6%), healed arteritis (2%), arteriosclerosis (67%), atherosclerosis (5%), or normal (3%). Most of the histological diagnoses made at the time of biopsy were confirmed but eight cases which had originally been reported as atypical or healed arteritis were classified as arteriosclerosis when reviewed. All 33 patients with histological evidence of arteritis were accepted as clinical cases of temporal arteritis (31) or polymyalgia rheumatica (2) and treated with steroids. A further 24 patients had negative biopsies (arteriosclerosis or atherosclerosis) but were considered on clinical grounds to have cranial arteritis. They too were treated and made a full recovery. In 43 cases, all of whom had negative biopsies, a final diagnosis was reached which was thought to account for the clinical symptoms (e.g., cerebrovascular accident, rheumatoid disease, migraine, etc.). As less than 60% of patients with clinical temporal arteritis had positive biopsies, we suggest that this procedure could be omitted and replaced by a trial of steroid therapy. Biopsy should be reserved for patients with a strong medical contraindication to steroid therapy, or who fail to respond to treatment promptly.

Entities:  

Mesh:

Year:  1981        PMID: 7270780     DOI: 10.1097/00000478-198106000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  18 in total

1.  Temporal artery biopsy: is there any value in examining biopsies at multiple levels?

Authors:  A Chakrabarty; A J Franks
Journal:  J Clin Pathol       Date:  2000-02       Impact factor: 3.411

2.  Clinical course and management of a consecutive series of patients with "healed temporal arteritis".

Authors:  Yvonne C Lee; Robert F Padera; Erika H Noss; Anne H Fossel; Don Bienfang; Matthew H Liang; William P Docken
Journal:  J Rheumatol       Date:  2011-12-01       Impact factor: 4.666

Review 3.  Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy; Javier Martin
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

4.  Relationship between histological subtypes and clinical characteristics at presentation and outcome in biopsy-proven temporal arteritis. Identification of a relatively benign subgroup.

Authors:  E J ter Borg; H C M Haanen; C A Seldenrijk
Journal:  Clin Rheumatol       Date:  2006-07-01       Impact factor: 2.980

5.  The influence of sectional interval on the reliability of temporal arterial biopsies in polymyalgia rheumatica.

Authors:  E Nordborg; C Nordborg
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

6.  Clinical usefulness of temporal artery biopsy.

Authors:  J Vilaseca; A González; M C Cid; J Lopez-Vivancos; A Ortega
Journal:  Ann Rheum Dis       Date:  1987-04       Impact factor: 19.103

7.  Temporal artery biopsy.

Authors:  M C Allison
Journal:  BMJ       Date:  1988-10-15

Review 8.  Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.

Authors:  Christian Dejaco; Elisabeth Brouwer; Justin C Mason; Frank Buttgereit; Eric L Matteson; Bhaskar Dasgupta
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

9.  Steroid sensitive systemic disease with anaemia in the elderly: a manifestation of giant cell arteritis?

Authors:  M C Allison; K R Gough
Journal:  Postgrad Med J       Date:  1985-06       Impact factor: 2.401

Review 10.  Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.

Authors:  Dario Camellino; Eric L Matteson; Frank Buttgereit; Christian Dejaco
Journal:  Nat Rev Rheumatol       Date:  2020-08-05       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.